{"data":[{"accessionNo":"0001104659-26-069556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares, no par value per share","eventDate":"2026-05-26","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":3850385,"percentOfClass":5.5,"filedAt":"2026-06-02"},{"accessionNo":"0001104659-26-069556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares, no par value per share","eventDate":"2026-05-26","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":3850385,"percentOfClass":5.5,"filedAt":"2026-06-02"},{"accessionNo":"0001104659-26-069556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares, no par value per share","eventDate":"2026-05-26","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":3850385,"percentOfClass":5.5,"filedAt":"2026-06-02"},{"accessionNo":"0001104659-26-069556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares, no par value per share","eventDate":"2026-05-26","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":3850385,"percentOfClass":5.5,"filedAt":"2026-06-02"},{"accessionNo":"0000935836-26-000279","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares","eventDate":"2026-03-31","reportingPerson":"Stonepine Capital, L.P.","reportingCik":null,"personType":"PN","sharesOwned":7594166,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0000935836-26-000279","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares","eventDate":"2026-03-31","reportingPerson":"Jon M. Plexico","reportingCik":null,"personType":"HC,IN","sharesOwned":7594166,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0000935836-26-000279","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares","eventDate":"2026-03-31","reportingPerson":"Stonepine GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":7594166,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0000935836-26-000279","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares","eventDate":"2026-03-31","reportingPerson":"Stonepine Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":7594166,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-03-31","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":102883,"percentOfClass":4.9,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-03-31","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":102846,"percentOfClass":4.9,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-03-31","reportingPerson":"Daniel Schneeberger","reportingCik":null,"personType":"HC,IN","sharesOwned":102846,"percentOfClass":4.9,"filedAt":"2026-05-15"},{"accessionNo":"0000919574-26-003240","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"Ordinary Shares, no par value per share","eventDate":"2026-03-31","reportingPerson":"Woodline Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2785370,"percentOfClass":4.4,"filedAt":"2026-05-15"},{"accessionNo":"0001716774-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-04-01","reportingPerson":"Aberdeen Group plc","reportingCik":null,"personType":"HC","sharesOwned":75000,"percentOfClass":4.16,"filedAt":"2026-04-29"},{"accessionNo":"0001716774-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":"74907L409","securityClass":"American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-04-01","reportingPerson":"abrdn Inc.","reportingCik":null,"personType":"CO,IA","sharesOwned":75000,"percentOfClass":4.16,"filedAt":"2026-04-29"},{"accessionNo":"0000902664-26-001060","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Woodline Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2785370,"percentOfClass":9.5,"filedAt":"2026-02-17"},{"accessionNo":"0001104659-26-016659","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":58230,"percentOfClass":6.9,"filedAt":"2026-02-17"},{"accessionNo":"0001104659-26-016659","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Daniel Schneeberger","reportingCik":null,"personType":"HC,IN","sharesOwned":58230,"percentOfClass":6.9,"filedAt":"2026-02-17"},{"accessionNo":"0001104659-26-016659","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":50226,"percentOfClass":6,"filedAt":"2026-02-17"},{"accessionNo":"0001104659-26-013497","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2618595,"percentOfClass":4.6,"filedAt":"2026-02-11"},{"accessionNo":"0001104659-26-013497","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":2618595,"percentOfClass":4.6,"filedAt":"2026-02-11"},{"accessionNo":"0001104659-26-013497","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2618595,"percentOfClass":4.6,"filedAt":"2026-02-11"},{"accessionNo":"0001104659-26-013497","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":2618595,"percentOfClass":4.6,"filedAt":"2026-02-11"},{"accessionNo":"0001193125-26-041438","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-01-31","reportingPerson":"Neil Shahrestani","reportingCik":null,"personType":"IN,HC","sharesOwned":211538,"percentOfClass":12.6,"filedAt":"2026-02-06"},{"accessionNo":"0001193125-26-041438","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2026-01-31","reportingPerson":"Ikarian Capital, LLC","reportingCik":null,"personType":"IA","sharesOwned":211538,"percentOfClass":12.6,"filedAt":"2026-02-06"},{"accessionNo":"0000935836-26-000065","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2026-01-29","reportingPerson":"Stonepine Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":3271100,"percentOfClass":10.6,"filedAt":"2026-02-02"},{"accessionNo":"0000935836-26-000065","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2026-01-29","reportingPerson":"Jon M. Plexico","reportingCik":null,"personType":"HC,IN","sharesOwned":3271100,"percentOfClass":10.6,"filedAt":"2026-02-02"},{"accessionNo":"0000935836-26-000065","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2026-01-29","reportingPerson":"Stonepine GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":3271100,"percentOfClass":10.6,"filedAt":"2026-02-02"},{"accessionNo":"0000935836-26-000065","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2026-01-29","reportingPerson":"Stonepine Capital, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3271100,"percentOfClass":10.6,"filedAt":"2026-02-02"},{"accessionNo":"0001716774-26-000006","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"abrdn Inc.","reportingCik":null,"personType":"CO,IA","sharesOwned":75000,"percentOfClass":8.94,"filedAt":"2026-01-28"},{"accessionNo":"0001716774-26-000006","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-12-31","reportingPerson":"Aberdeen Group plc","reportingCik":null,"personType":"HC","sharesOwned":75000,"percentOfClass":8.94,"filedAt":"2026-01-28"},{"accessionNo":"0000935836-25-000719","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2025-12-10","reportingPerson":"Stonepine Capital, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3030926,"percentOfClass":9.9,"filedAt":"2025-12-16"},{"accessionNo":"0000935836-25-000719","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2025-12-10","reportingPerson":"Jon M. Plexico","reportingCik":null,"personType":"HC,IN","sharesOwned":3030926,"percentOfClass":9.9,"filedAt":"2025-12-16"},{"accessionNo":"0000935836-25-000719","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2025-12-10","reportingPerson":"Stonepine GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":3030926,"percentOfClass":9.9,"filedAt":"2025-12-16"},{"accessionNo":"0000935836-25-000719","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares","eventDate":"2025-12-10","reportingPerson":"Stonepine Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":3030926,"percentOfClass":9.9,"filedAt":"2025-12-16"},{"accessionNo":"0001193125-25-319730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-11-30","reportingPerson":"Neil Shahrestani","reportingCik":null,"personType":"IN,HC","sharesOwned":211538,"percentOfClass":25.2,"filedAt":"2025-12-15"},{"accessionNo":"0001193125-25-319730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share","eventDate":"2025-11-30","reportingPerson":"Ikarian Capital, LLC","reportingCik":null,"personType":"IA","sharesOwned":211538,"percentOfClass":25.2,"filedAt":"2025-12-15"},{"accessionNo":"0001834913-25-000006","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, Each representing thirty-five(35) ordinary shares, no par value per share","eventDate":"2025-10-10","reportingPerson":"Resolute Capital Asset Partners Fund I LP","reportingCik":null,"personType":"OO,PN","sharesOwned":50000,"percentOfClass":8.5,"filedAt":"2025-12-11"},{"accessionNo":"0001834913-25-000006","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","cusip":null,"securityClass":"American Depositary Shares, Each representing thirty-five(35) ordinary shares, no par value per share","eventDate":"2025-10-10","reportingPerson":"Resolute Capital Asset Partners LLC","reportingCik":null,"personType":"IA","sharesOwned":50000,"percentOfClass":8.5,"filedAt":"2025-12-11"},{"accessionNo":"0001104659-25-102609","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-10-20","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":1901585,"percentOfClass":9,"filedAt":"2025-10-27"},{"accessionNo":"0001104659-25-102609","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-10-20","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":1901585,"percentOfClass":9,"filedAt":"2025-10-27"},{"accessionNo":"0001104659-25-102609","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-10-20","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":1901585,"percentOfClass":9,"filedAt":"2025-10-27"},{"accessionNo":"0001104659-25-102609","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001671502","issuerName":"Quoin Pharmaceuticals Ltd.","ticker":"QNRX","cusip":null,"securityClass":"Ordinary Shares, no par value per share","eventDate":"2025-10-20","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":1901585,"percentOfClass":9,"filedAt":"2025-10-27"}],"updatedAt":"2026-09-19T02:18:41.155Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data"}